Mucinous Ovarian Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Clinical Trials

Bevacizumab Plus Modified FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma, Single-arm, Phase II Study
Conditions:   Mucinous Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer Intervention:   Drug: Bevacizumab + modified FOLFIRINOX Sponsor:   Yonsei University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials

Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
Conditions:   Mucinous Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer Intervention:   Drug: Bevacizumab + modified FOLFIRINOX Sponsor:   Yonsei University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials

Bevacizumab Plus Modified FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma, Single-arm, Phase II Study
Conditions:   Mucinous Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer Intervention:   Drug: Bevacizumab + modified FOLFIRINOX Sponsor:   Yonsei University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 26, 2022 Category: Research Source Type: clinical trials